Resource Center

www.lls.org/resourcecenter

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:

donate

May 29, 2013 - PTCL - Diagnosis & Treatment Update

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: Wednesday, May 29, 2013
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
Read: Program Slides | Transcript
Listen: Presentation | Q&A Session

Topics Covered

  • PTCL and PTCL subtypes
  • Treatment options for patients with newly diagnosed, refractory or relapsed PTCL
  • The role of clinical trials as treatment options for patients with PTCL
  • Patient-provider communications about treatment options, including clinical trials
  • Patient-provider communications about side effects management

Speaker

Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief
, Division of Oncology/Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Questions Asked by the PTCL Community

  • Are there any blood tests which might be an early detector of recurrence?
  • What are the standards of initial medical evaluation and then diagnosis, if there aren't any enlarged nodes and a biopsy can't be done?
  • Can a diagnosis of PTCL linger on at a treatable level without significant increase in severity?
  • Are there any topical treatments or other medications that you can suggest to help relieve itching?
  • Can you please talk about the status of denileukin diftitox (Ontak®) as a targeted therapy?
    Is this common to have both an autologous transplant and an allogeneic transplant to treat angioimmunoblastic T-cell lymphoma?
  • What is the success rate of an allogeneic transplant?
  • If the disease comes back, is getting another biopsy necessary to try to understand how to best treat it?
  • Is it true that young male males, treated for inflammatory bowel disease, are at risk of developing hepatosplenic T-cell lymphoma and is it because of the treatment for IBD? And if so, how can that risk be reduced?
  • What is the relationship between Epstein-Barr virus and PTCL?
  • What are the long range effects of taking the drug vorinostat (Zolinza®) at 400 milligrams daily for about three years?
  • What would be the best treatment for pediatric ALK-positive anaplastic large cell lymphoma?
  • Is there any relationship between sarcoidosis and PTCL and is it possible to confuse the diagnosis?
  • Can you explain the diagnosis of PTCL with a cytotoxic T-cell phenotype?
  • Do you know anything about intravenous Vitamin C as an adjunct therapy on an individual basis?
  • Can you please talk about the role of PUVA or light therapy in the treatment of PTCL?
  • What types of T-cell lymphomas does alisertib (MLN8237) have activity with?
  • With autologous transplant, is the survival rate better now than it used to be?
  • How does a patient feel after the first cycle of chemotherapy and what kinds of side effects are expected?
  • Is there a maximum number of pralatrexate (Folotyn®) cycles that can be given and is a PET/CT scan necessary after each cycle?
  • Can peripheral T-cell lymphoma transform into any other type of T-cell lymphoma?
  • What are the chances of relapse after being in remission following an autologous transplant?
  • Could you please discuss why the peripheral T-cell lymphomas are most often diagnosed at an advanced stage, where they're already stage III or IV, and how does this compare to other lymphomas?
  • Is fatigue common after an autologous transplant and are there any recommendations to help alleviate the fatigue?
  • Is romidepsin (Istodax®) a good choice to be taking after receiving an autologous transplant and relapsing?
  • Is staying in remission largely now a function of maintaining and strengthening the immune system or do you have any other suggestions to help eradicate the cancer cells or to help keep them under control?
  • How can a patient find out more information about clinical trials and are there any suggestions that you can provide about that topic?
  •  Are mycosis fungoides and Sezary syndrome the same?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by a grant from Celgene Corporation.

last updated on Thursday, July 10, 2014
btn_sharethis